Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.

2.

The Kansas Cancer Center awarded two Indian American doctors professorships.

3.

A new theranostic drug targets different cancer types.

4.

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

5.

Antibiotic Stewardship: Five Tips to Reduce Resistance


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot